Carfilzomib achieved an ORR of 24% and a median duration of response of 7.4 months in that open label single arm phase IIb trial. Looks good enough for approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.